Form 4: Kymera CBO Goodman Receives Equity Grants

Kymera Therapeutics' Chief Business Officer, Noah Goodman, was granted 9,225 restricted stock units and options for 18,450 shares, vesting over several years.

Summary

• Noah Goodman, Chief Business Officer of Kymera Therapeutics, Inc. (KYMR), received new equity grants.
• He was granted 9,225 restricted stock units (RSUs) on March 2, 2026, which will vest in four equal annual installments starting from that date, contingent on his continued employment.
• Additionally, he was granted stock options to purchase 18,450 shares of common stock at an exercise price of $90.1 per share, also on March 2, 2026.
• These stock options will vest in forty-eight equal monthly installments following March 2, 2026, subject to his continued employment, and expire on March 1, 2036.
• Following these transactions, Goodman beneficially owns 59,306.438 shares of common stock directly and 18,450 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive incentivization and retention practices. It signals continued commitment to the Chief Business Officer and aligns his interests with long-term company performance.

Positives

• Grant of 9,225 restricted stock units (RSUs) to the Chief Business Officer, aligning his interests with shareholders.
• Grant of stock options for 18,450 shares at an exercise price of $90.1, providing long-term incentive.
• The equity grants indicate continued commitment and incentivization of a key executive.

Future Outlook

The restricted stock units will vest in four equal annual installments following March 2, 2026, and the stock options will vest in forty-eight equal monthly installments following March 2, 2026, both contingent on continued employment. This indicates a long-term incentive structure for the Chief Business Officer.

Industry Context

StockSavvy.ai notes that equity grants, particularly RSUs and stock options with multi-year vesting schedules, are standard practice in the biotechnology and pharmaceutical industries for executive compensation. This practice aims to align executive incentives with long-term shareholder value creation and retain key talent in a competitive sector.

Comparison to Industry Standards

• The structure of multi-year vesting for both RSUs (four annual installments) and stock options (48 monthly installments) is consistent with typical executive compensation packages in the biotech industry, similar to practices seen at companies like Moderna or BioNTech for their senior executives, designed to ensure long-term commitment and performance.
• The grant size for a Chief Business Officer at a company like Kymera Therapeutics, which is a clinical-stage biopharmaceutical company, appears within a reasonable range for incentivizing a key executive responsible for strategic partnerships and commercial development, comparable to grants observed at similar-stage companies.

Stakeholder Impact

• Shareholders: The grants align the Chief Business Officer's interests with shareholder value creation, as the value of his equity is tied to the company's stock performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• Vesting of 9,225 restricted stock units in four equal annual installments following March 2, 2026.
• Vesting of 18,450 stock options in forty-eight equal monthly installments following March 2, 2026.
• Continued employment of Noah Goodman through each vesting date.

Key Dates

Recommendation

This Form 4 filing details routine equity grants to a key executive. While positive for executive retention and alignment, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It's a standard compensation event.

Keywords

Kymera Therapeutics, KYMR, Noah Goodman, Chief Business Officer, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, SEC Form 4